A double-blind dose-escalating study of LT-3001 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs LT 3001 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 03 Aug 2017 Planned number of patients changed to 80.
- 03 Aug 2017 New trial record
- 28 Jul 2017 According to a Lumosa Therapeutics media release, first human subject was dosed with LT3001 in California.